Ionis Pharmaceuticals (IONS) Stock Looks Fully Priced After FDA Rare Disease Approval

Ionis Pharmaceuticals received FDA approval for ZANVASTRO targeting a rare disease, boosting its rare disease franchise potential, but valuation metrics suggest its stock is fully priced with limited upside from current portfolio and pipeline risks.

This Wire brief sits within Fusion42's coverage of Biotech.